KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer

被引：25

作者：

Jimeno, Antonio ^{[1
]}

Messersmith, Wells A. ^{[1
]}

Hirsch, Fred R. ^{[1
]}

Franklin, Wilbur A. ^{[1
]}

Eckhardt, S. Gail ^{[1
]}

机构：

[1] Univ Colorado, Ctr Canc, Denver, CO 80262 USA

来源：

CANCER JOURNAL | 2009年 / 15卷 / 02期

关键词：

KRAS; EGFR; biomarker; colorectal cancer; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; K-RAS MUTATIONS; POINT MUTATIONS; EGFR; INHIBITOR; IDENTIFICATION; HYBRIDIZATION; CHEMOTHERAPY; ONCOGENES;

D O I：

10.1097/PPO.0b013e31819e3202

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent retrospective evidence from several randomized studies has established that advanced colorectal cancer patients with tumors harboring a mutation in the KRAS gene do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitumumab. This represents a paradigm-changing event and will have substantial impact on current and future anticancer drug development. These results add to the economic and ethical considerations involved in the development of novel targeted therapies and should increase our scrutiny of mechanisms of resistance and predictive biomarkers while in earlier developmental stages. In this article. we will review the available clinical data and discuss the implications for future drug development in colorectal cancer.

引用

页码：110 / 113

页数：4

共 43 条

[1] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].

Adjei, Alex A. ;

Cohen, Roger B. ;

Franklin, Wilbur ;

Morris, Clive ;

Wilson, David ;

Molina, Julian R. ;

Hanson, Lorelei J. ;

Gore, Lia ;

Chow, Laura ;

Leong, Stephen ;

Maloney, Lara ;

Gordon, Gilad ;

Simmons, Heidi ;

Marlow, Allison ;

Litwiler, Kevin ;

Brown, Suzy ;

Poch, Gregory ;

Kane, Katie ;

Haney, Jerry ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146

[2] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[3] Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[4] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[5] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

De Braud, F. G. ;

Volovat, C. ;

Nippgen, J. ;

Stroh, C. ;

Celik, I. ;

Koralewski, P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[6] EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients [J].

Cappuzzo, F. ;

Finocchiaro, G. ;

Rossi, E. ;

Jaenne, P. A. ;

Carnaghi, C. ;

Calandri, C. ;

Bencardino, K. ;

Ligorio, C. ;

Ciardiello, F. ;

Pressiani, T. ;

Destro, A. ;

Roncalli, M. ;

Crino, L. ;

Franklin, W. A. ;

Santoro, A. ;

Varella-Garcia, M. .

ANNALS OF ONCOLOGY, 2008, 19 (04) :717-723

[7] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].

Chung, KY ;

Shia, J ;

Kemeny, NE ;

Shah, M ;

Schwartz, GK ;

Tse, A ;

Hamilton, A ;

Pan, D ;

Schrag, D ;

Schwartz, L ;

Klimstra, DS ;

Fridman, D ;

Kelsen, DP ;

Saltz, LB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810

[8]

Clayton SJ, 2000, CLIN CHEM, V46, P1929

[9] DETECTION OF SICKLE-CELL BETA-S-GLOBIN ALLELE BY HYBRIDIZATION WITH SYNTHETIC OLIGONUCLEOTIDES [J].

CONNER, BJ ;

REYES, AA ;

MORIN, C ;

ITAKURA, K ;

TEPLITZ, RL ;

WALLACE, RB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (01) :278-282

[10] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

← 1 2 3 4 5 →